Skip to content

Cancer Health Center

Font Size

Childhood Rhabdomyosarcoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (08 / 19 / 2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information

Recommended Related to Cancer


Coenzyme Q10 (commonly known as CoQ10) is a compound that is made naturally in the body. The body uses it for cell growth and to protect cells from damage that could lead to cancer (see Question 1). Animal studies have shown that CoQ10 helps the immune system work better and makes the body better able to resist certain infections and types of cancer (see Question 5). Clinical trials have shown that CoQ10 helps protect the heart from the damaging side effects of doxorubicin, a drug...

Read the Overview article > >

Added Smith et al. as reference 1.

Revised text to state that between 1975 and 2010, childhood cancer mortality decreased by more than 50%; for rhabdomyosarcoma, the 5-year survival rate increased over the same time, from 53% to 67% for children younger than 15 years and from 30% to 51% for adolescents aged 15 to 19 years.

Added text to state that it is unclear whether response to induction chemotherapy, as judged by anatomic imaging, correlates with the likelihood of survival in patients with rhabdomyosarcoma, because the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group studies found no association (cited Rosenberg et al. as reference 36 and level of evidence 3iiDi). However, an Italian study found that patient response did correlate with likelihood of survival.

Cellular Classification

Revised text about alveolar histology to state that about 70% to 80% of alveolar tumors are characterized by translocations between the FOXO1 gene on chromosome 13 and either the PAX3 gene on chromosome 2 or PAX7 gene on chromosome 1. Also added text to state that other rare fusions include PAX-NCOA1 and PAX3-INO80D (cited Shern et al. as reference 14).

Added text to state that in addition to FOXO1 rearrangements, alveolar tumors are characterized by a lower mutational burden than are fusion-negative tumors, with fewer genes having recurring mutations; BCOR and PIK3CA mutations and the amplification of MYCN, MIR17HG, and CDK4 have also been described (cited Chen et al. as reference 22).

Added text to state that embryonal tumors show loss of heterozygosity at 11p15 and gains on chromosome 8; embryonal tumors have a higher background mutation and higher single-nucleotide variant rate than do alveolar tumors, and the number of somatic mutations increases with older age at diagnosis. Also added text to state that genes with recurring mutations include those in the RAS pathway, which together are observed in approximately one-third of cases; other genes with recurring mutations include FGFR4, PIK3CA, CTNNB1, FBXW7, and BCOR, all of which are present in fewer than 10% of cases.

    Next Article:

    Today on WebMD

    Colorectal cancer cells
    New! I AM Not Cancer Facebook Group
    Lung cancer xray
    See it in pictures, plus read the facts.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Real Cancer Perspectives
    Jennifer Goodman Linn self-portrait
    what is your cancer risk
    colorectal cancer treatment advances
    breast cancer overview slideshow
    prostate cancer overview
    lung cancer overview slideshow
    ovarian cancer overview slideshow
    Actor Michael Douglas